Share This Article:

Comparison on the Pharmacokinetics and Weight Reduction of Clobenzorex Slow Release and Immediate Release Formulations in Obese Patients

Abstract Full-Text HTML XML Download Download as PDF (Size:172KB) PP. 218-221
DOI: 10.4236/pp.2013.42030    5,287 Downloads   7,989 Views   Citations


Clobenzorex is an anorexigenic drug that is widely used in Mexicofor the treatment of obesity, since it helps to reduce body weight. This drug is available as immediate release capsules. To improve compliance to treatment, it was developed a new slow release formulation. In order to establish its usefulness, oral pharmacokinetics and weight reduction of slow release and immediate release formulations of clobenzorex in obese patients were compared. Sixty patients with a BMI higher than 27 kg/m2 were included in the study. Two groups of 30 patients were formed, one of them received 30 mg immediate release formulation b.i.d. and the other group received one 60 mg slow release formulation once a day, since under this scheme these formulations are prescribed. Blood samples were obtained at selected times during the first day and once weekly during 4 weeks. After the last dose, samples were obtained at selected times during 48 h. Plasma levels were determined by HPLC-MS/MS and pharmacokinetic parameters were obtained. Reduction in Cmax due to increased tmax, as well as, increased half-life were observed with the slow release formulation in comparison with immediate release formulation. Although lower plasma levels of clobenzorex were reached with the slow release formulation, reduction of body weight was similar with both products. Based on the results, it was concluded that slow release formulation of clobenzorex is an adequate formulation of clobenzorex, since pharmacokinetics and effects observed are compatible with a once a day administration.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

F. Argüelles-Tello, M. Carrasco-Portugal, N. Carrasco-Portugal, J. Aguilar-Carrasco, S. Patiño-Camacho, C. Valle, G. Reyes-Garcia and F. Flores-Murrieta, "Comparison on the Pharmacokinetics and Weight Reduction of Clobenzorex Slow Release and Immediate Release Formulations in Obese Patients," Pharmacology & Pharmacy, Vol. 4 No. 2, 2013, pp. 218-221. doi: 10.4236/pp.2013.42030.


[1] B. Glasson, A. Benakis and M. Thomasset, “Localisation, Distribution, Excretion et Metabolisme d’eun Nouveau Medicament Anorexigene Marqué au C14: Le Cholhydrate de Clobenzorex,” Arzneim-Forsch, Vol. 21, 1971, pp. 1985-1992.
[2] S. Valtier and J. T. Cody, “Differentiation of Clobenzorex Use from Amphetamine Abuse Using the Metabolite 4-Hydroxyclobenzorex,” Journal of Analytical Toxicology, Vol. 24, No. 7, 2000, pp. 606-613. doi:10.1093/jat/24.7.606
[3] K. L. Baden, S. Valtier and J. T. Cody, “Metabolic Production of Amphetamine Following Multidose Administration of Clobenzorex,” Journal of Analytical Toxicology, Vol. 23, No. 6, 1999, pp. 511-517. doi:10.1093/jat/23.6.511
[4] J. T. Cody and S. Valtier, “A Gas Chromatography-Mass Spectrometry Method for the Quantitation of Clobenzorex,” Journal of Analytical Toxicology, Vol. 23, 1999, pp. 603-608.
[5] Goodman and Gilman, “Las Bases Farmacológicas de la Terapéutica,” Décima Edición, McGraw Hill, New York, 2006, pp. 223-275.
[6] M. Rowland and T. N. Tozer, “Clinical Pharmacokinetics. Concepts and Applications,” 3rd Edition, Lea & Febiger, Philadelphia, London, 1995.

comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.